Nuvalent (NUVL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO, with all board members and key executives introduced.
Meeting held virtually, following the format from the previous year.
Rules of conduct and participation outlined for attendees.
Corporate governance
Notice of meeting and proxy statement were sent to all stockholders of record as of April 20, 2026.
Quorum established with a majority of Class A common stock represented.
Board and executive committee updates
Election of two Class 2 directors for a three-year term was on the agenda.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Nuvalent
- Neladalkib achieves durable efficacy and strong CNS activity in ALK-positive NSCLC.NUVL
Study Update9 Jul 2026 - Pivotal data and regulatory filings for ALK and ROS1 programs are expected in 2024.NUVL
TD Cowen 45th Annual Healthcare Conference9 Jul 2026 - Pivotal ROS1 data release imminent, with broad inclusion and focus on rapid, differentiated approvals.NUVL
TD Cowen's 6th Annual Oncology Innovation Summit8 Jul 2026 - Durable responses and strong enrollment position both lead programs for pivotal data in 2025.NUVL
European Society for Medical Oncology Congress (ESMO) 20248 Jul 2026 - Advancing global launches of innovative NSCLC therapies with strong clinical and financial momentum.NUVL
Guggenheim Securities Emerging Outlook: Biotech Summit 202630 Jun 2026 - Two major drug launches in 2024, with neladalkib poised to shift ALK treatment standards.NUVL
Jefferies Global Healthcare Conference 20264 Jun 2026 - Two commercial launches and pivotal trial progress position the pipeline for major impact in oncology.NUVL
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA27 May 2026 - Pivotal data for lead NSCLC therapies support 2026 launches and strong market growth.NUVL
Corporate presentation27 May 2026 - Q1 2026 net loss was $109.3M as lead oncology programs reached NDA stage and cash stood at $1.3B.NUVL
Q1 20267 May 2026